Biotech

FDA lifts clinical hold on Curis' phase 1/2 lymphoma trial

The FDA has lifted a clinical hold on Curis' phase 1/2 lymphoma trial assessing its drug emavusertib, sending the biotech's stocks soaring.

Gabrielle Masson Aug 18, 2022 11:23am

Bayer dumps Exscientia AI deal, leaving target to drug hunter

Aug 18, 2022 10:00am

CureVac, GSK load into starting block in omicron booster race

Aug 18, 2022 9:10am

Astellas' menopause therapy accepted for FDA review

Aug 18, 2022 8:50am

China's Jemincare nabs $650M biobucks pact with Genentech

Aug 18, 2022 7:08am

Omeros' Hail Mary throw for blood clot med delayed at FDA

Aug 17, 2022 11:21am